Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival

Sang Hyeok Woo; Vlad C Sandulache; Liangpeng Yang; Heath D Skinner

doi:10.1007/978-1-4939-0856-1_2

Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival

Methods Mol Biol. 2014:1165:11-8. doi: 10.1007/978-1-4939-0856-1_2.

Authors

Sang Hyeok Woo¹, Vlad C Sandulache, Liangpeng Yang, Heath D Skinner

Affiliation

¹ Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

PMID: 24839015
DOI: 10.1007/978-1-4939-0856-1_2

Abstract

Metformin is a commonly utilized antidiabetic agent, which has been associated with improved clinical outcomes in cancer patients. The precise mechanism of action remains unclear, but preclinical evidence suggests that metformin can sensitize tumor cells to the effects to conventional chemotherapeutic agents and ionizing radiation (IR). In this chapter we describe two assays to investigate the effects of combination of metformin and a chemotherapeutic agent (in this case cisplatin) in head and neck cancer squamous cell carcinoma (HNSCC) cell lines.

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / pharmacology*
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Squamous Cell / pathology*
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Survival / drug effects
Cisplatin / administration & dosage
Cisplatin / pharmacology*
Glycolysis / drug effects
Head and Neck Neoplasms / pathology*
Humans
Metformin / administration & dosage
Metformin / pharmacology*
Mitochondria / enzymology
Squamous Cell Carcinoma of Head and Neck

Substances

Antineoplastic Agents
Metformin
Cisplatin